Special Issue

Adiposity, Inflammation, and Metabolic Regulation: Molecular Mechanisms and Therapeutic Strategies

Message from the Guest Editor

To advance our knowledge in this critical area, this Special Issue invites original research and review articles that explore the following (but are not limited to them):

- The interrelationships between obesity and insulin resistance/hyperinsulinemia.
- The cellular and molecular mechanisms governing adipocyte differentiation, function, and dysfunction.
- The role of inflammation in adipose tissue, including the involvement of immune cells and inflammatory signaling pathways.
- The complex interplay between adipose tissue, systemic metabolism, and the development of obesity-related complications.
- Novel therapeutic approaches targeting adipose tissue biology and inflammation for the prevention and treatment of obesity.

We encourage submissions that contribute to a comprehensive understanding of obesity pathogenesis and inform the development of innovative treatment strategies. We look forward to receiving your contributions.

Guest Editor

Dr. Qianfen Wan

Naomi Berrie Diabetes Center, Columbia University, New York, NY 10032, USA

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/214096

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).